BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Somaliland denies trading recognition with Israel for accepting Gazans - 2Tech Patterns 2023: 12 Advancements to Keep an eye Out For
- 3Figure out How to Score Huge with Open Record Rewards
- 4Who is Artemis? Meet the Greek goddess who inspired NASA's return to the moon
- 5Man threatens attack on German high-speed train, injures several
- Geminid meteor shower 2025 peaks next week. Here's what you need to know about this year's best meteor shower
- Louisiana seeks California doctor’s extradition, testing the limits of shield laws
- Blake Lively's sexual harassment claims against Justin Baldoni dismissed. Where the case stands now.
- She was the supermodel dubbed 'The Face' in the '80s. Joining OnlyFans in her 60s taught her a lot.
- The Solution to Flexibility: Developing Internal Fortitude Notwithstanding Misfortune
- Why won't NASA's Artemis 2 astronauts land on the moon when they get there?
- Involved Vehicles for Seniors: Track down the Best Picks for Solace and Dependability
- RFK Jr. wants to scrutinize the vaccine schedule – but its safety record is already decades long
- Ukraine proved this drone-killer works. Now, the West is giving it a shot.
